JP2025065142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025065142A5 JP2025065142A5 JP2025004349A JP2025004349A JP2025065142A5 JP 2025065142 A5 JP2025065142 A5 JP 2025065142A5 JP 2025004349 A JP2025004349 A JP 2025004349A JP 2025004349 A JP2025004349 A JP 2025004349A JP 2025065142 A5 JP2025065142 A5 JP 2025065142A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- fragment
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425398P | 2016-11-22 | 2016-11-22 | |
| US62/425,398 | 2016-11-22 | ||
| US201762543696P | 2017-08-10 | 2017-08-10 | |
| US62/543,696 | 2017-08-10 | ||
| PCT/US2017/063048 WO2018098306A1 (en) | 2016-11-22 | 2017-11-22 | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| JP2019547605A JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2023012793A JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023012793A Division JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025065142A JP2025065142A (ja) | 2025-04-17 |
| JP2025065142A5 true JP2025065142A5 (https=) | 2025-05-09 |
Family
ID=62193475
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2023012793A Pending JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2025004349A Pending JP2025065142A (ja) | 2016-11-22 | 2025-01-10 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019547605A Active JP7778468B2 (ja) | 2016-11-22 | 2017-11-22 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
| JP2023012793A Pending JP2023059873A (ja) | 2016-11-22 | 2023-01-31 | Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10550183B2 (https=) |
| EP (1) | EP3545082A4 (https=) |
| JP (3) | JP7778468B2 (https=) |
| KR (2) | KR20190085528A (https=) |
| CN (3) | CN118581046A (https=) |
| AU (3) | AU2017363278B2 (https=) |
| CA (1) | CA3043752A1 (https=) |
| NZ (1) | NZ752984A (https=) |
| SG (2) | SG11201903830TA (https=) |
| WO (1) | WO2018098306A1 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11304288B2 (en) | 2014-01-31 | 2022-04-12 | Monolith Materials, Inc. | Plasma torch design |
| US11987712B2 (en) | 2015-02-03 | 2024-05-21 | Monolith Materials, Inc. | Carbon black generating system |
| CN113713091A (zh) | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| CN111601447A (zh) | 2015-07-29 | 2020-08-28 | 巨石材料公司 | Dc等离子体焰炬电力设计方法和设备 |
| CN108350280A (zh) | 2015-08-07 | 2018-07-31 | 巨石材料公司 | 炭黑的制造方法 |
| US20170066923A1 (en) | 2015-09-09 | 2017-03-09 | Monolith Materials, Inc. | Circular few layer graphene |
| NZ750256A (en) | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| SG11201903830TA (en) | 2016-11-22 | 2019-05-30 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| CA3287539A1 (en) | 2017-06-21 | 2026-03-02 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| KR20210008408A (ko) | 2018-05-23 | 2021-01-21 | 싱가포르국립대학교 | T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단 |
| US10227576B1 (en) * | 2018-06-13 | 2019-03-12 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US12227776B2 (en) | 2018-06-13 | 2025-02-18 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| KR102665280B1 (ko) * | 2018-10-31 | 2024-05-10 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거 |
| SG11202104524YA (en) * | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| KR20210091250A (ko) | 2018-11-14 | 2021-07-21 | 메디식스 테라퓨틱스 피티이 엘티디. | Car-t 세포를 생성하기 위한 이중유전자 벡터 및 이의 용도 |
| CN109652379B (zh) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| CA3139346A1 (en) | 2019-05-07 | 2020-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cell targeting bcma and use thereof |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| KR20220095193A (ko) * | 2019-10-11 | 2022-07-06 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 조절 가능한 세포 국재화를 위한 재조합 폴리펩티드 |
| CN120905142A (zh) * | 2019-11-20 | 2025-11-07 | 卡瑟里克斯私人有限公司 | 用于提供具有增强功能的免疫细胞的方法 |
| CA3160759A1 (en) * | 2019-12-05 | 2021-06-10 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| US20230019849A1 (en) * | 2019-12-09 | 2023-01-19 | St. Jude Children's Research Hospital, Inc. | Method for Preparing CD7-Negative, CD3-Positive T Cells |
| US12312407B2 (en) * | 2020-01-30 | 2025-05-27 | St Phi Therapeutics Co., Ltd. | Universal T cells and the method of use thereof |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| CN112300282A (zh) * | 2020-11-03 | 2021-02-02 | 南京北恒生物科技有限公司 | 靶向cd7的人源化抗体及其用途 |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| CN114525306B (zh) * | 2020-11-23 | 2025-01-28 | 博生吉医药科技(苏州)有限公司 | 一种cd7-car-t细胞的制备方法及应用 |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN115786271B (zh) * | 2021-01-12 | 2025-07-22 | 上海雅科生物科技有限公司 | 靶向cd7的工程化免疫细胞、嵌合抗原受体、cd7阻断分子及应用 |
| IL304904A (en) * | 2021-02-01 | 2023-10-01 | St Phi Therapeutics Co Ltd | Target protein degradation system and its use |
| US20240082306A1 (en) * | 2021-02-03 | 2024-03-14 | Bioheng Therapeutics Limited | Novel chimeric antigen receptor and use thereof |
| CN112980800A (zh) * | 2021-03-08 | 2021-06-18 | 河北森朗生物科技有限公司 | Car-t细胞、其构建方法及其应用 |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| CN112662631B (zh) * | 2021-03-16 | 2021-06-29 | 合源生物科技(天津)有限公司 | 一种car-t细胞灌流培养方法 |
| EP4326293A4 (en) | 2021-04-22 | 2025-03-12 | Baylor College of Medicine | METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY |
| US20250222026A1 (en) * | 2021-06-08 | 2025-07-10 | Beijing Meikang Geno-Immune Biotechnology Co., Ltd. | Cd7-based humanized chimeric antigen receptor and use thereof |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023155852A1 (zh) * | 2022-02-17 | 2023-08-24 | 上海优替济生生物医药有限公司 | 经修饰的免疫效应细胞及其用途 |
| CN114560943B (zh) * | 2022-02-28 | 2022-12-16 | 先进生物(苏州)有限公司 | Cd7-car-t细胞及其制备方法和应用 |
| US20250099504A1 (en) * | 2022-03-29 | 2025-03-27 | Institute Of Hematology And Blood Diseases Hospital , Chinese Academy Of Medical Sciences | Antibody that specifically binds to cd7 and use thereof in preparing chimeric antigen receptor |
| CN117004603A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种cd7基因被敲除的工程化免疫细胞及其用途 |
| CN120787162A (zh) | 2022-05-20 | 2025-10-14 | 诺华股份有限公司 | 抗肿瘤化合物的抗体-药物缀合物及其使用方法 |
| US20260061065A1 (en) | 2022-05-20 | 2026-03-05 | Novartis Ag | Antibody drug conjugates |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| EP4559937A1 (en) * | 2023-11-24 | 2025-05-28 | Universitat de Barcelona | Cd7 targeting moieties for the treatment of cd7 positive cancer |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2304208A1 (en) | 1997-09-19 | 1999-03-25 | Dana-Farber Cancer Institute, Inc. | Intrabody-mediated control of immune reactions |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| AU2002361390A1 (en) | 2001-12-14 | 2003-06-30 | Friedrich-Alexander-Universitaet Erlangen-Nuernberg | Anti-cd7 immunotoxin as fusion protein |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP2287195B1 (en) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| WO2006047637A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
| CN101675075B (zh) | 2007-03-01 | 2014-06-18 | 西福根有限公司 | 重组抗表皮生长因子受体抗体组合物 |
| DK2185574T3 (da) | 2007-09-07 | 2013-08-05 | Agensys Inc | Antistoffer og relaterede molekyler, der bindes til 24P4C12-proteiner |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| ES2826883T3 (es) | 2009-10-14 | 2021-05-19 | Janssen Biotech Inc | Métodos de maduración por afinidad de anticuerpos |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013126712A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093831A2 (en) * | 2012-12-14 | 2014-06-19 | Thomson Reuters (Markets) Llc | Dynamic function builder |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| WO2014106123A1 (en) | 2012-12-27 | 2014-07-03 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| SG11201507026WA (en) | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| PT2961831T (pt) | 2013-02-26 | 2020-10-12 | Memorial Sloan Kettering Cancer Center | Composições e métodos para imunoterapêutica |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| EP3057986B1 (en) | 2013-10-17 | 2017-12-27 | National University of Singapore | Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors |
| US20160296562A1 (en) | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| CA2943008C (en) | 2014-03-19 | 2021-03-30 | Cellectis | Cd123 specific chimeric antigen receptors for cancer immunotherapy |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| JP2017531430A (ja) | 2014-10-07 | 2017-10-26 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃａｒによって誘導される免疫細胞の活性を調節するための方法 |
| KR102376244B1 (ko) | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| CN113713091A (zh) | 2015-02-06 | 2021-11-30 | 新加坡国立大学 | 工程免疫细胞及其用途和生产方法 |
| JP7237449B2 (ja) | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| KR102133857B1 (ko) | 2015-03-02 | 2020-07-20 | 이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드 | Ｐｄ－ｌ１에 의해 유도된 면역관용의 감소 |
| GB201507104D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| US11390658B2 (en) * | 2016-06-06 | 2022-07-19 | St. Jude Children's Research Hospital | Anti-CD7 chimeric antigen receptor and method of use thereof |
| CA2937157A1 (en) | 2016-07-25 | 2018-01-25 | Ucl Business Ltd | Protein-based t-cell receptor knockdown |
| NZ750256A (en) * | 2016-08-03 | 2026-02-27 | Dipersio John F | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
| SG11201903830TA (en) | 2016-11-22 | 2019-05-30 | Nat Univ Singapore | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| KR20210091250A (ko) | 2018-11-14 | 2021-07-21 | 메디식스 테라퓨틱스 피티이 엘티디. | Car-t 세포를 생성하기 위한 이중유전자 벡터 및 이의 용도 |
-
2017
- 2017-11-22 SG SG11201903830TA patent/SG11201903830TA/en unknown
- 2017-11-22 KR KR1020197016703A patent/KR20190085528A/ko not_active Ceased
- 2017-11-22 NZ NZ752984A patent/NZ752984A/en unknown
- 2017-11-22 CA CA3043752A patent/CA3043752A1/en active Pending
- 2017-11-22 US US15/821,170 patent/US10550183B2/en active Active
- 2017-11-22 KR KR1020247020607A patent/KR102889007B1/ko active Active
- 2017-11-22 JP JP2019547605A patent/JP7778468B2/ja active Active
- 2017-11-22 CN CN202410674061.XA patent/CN118581046A/zh active Pending
- 2017-11-22 WO PCT/US2017/063048 patent/WO2018098306A1/en not_active Ceased
- 2017-11-22 SG SG10201912387PA patent/SG10201912387PA/en unknown
- 2017-11-22 US US15/821,153 patent/US11440958B2/en active Active
- 2017-11-22 EP EP17874643.4A patent/EP3545082A4/en active Pending
- 2017-11-22 AU AU2017363278A patent/AU2017363278B2/en active Active
- 2017-11-22 CN CN201780073071.6A patent/CN110268049B/zh active Active
- 2017-11-22 CN CN202410674086.XA patent/CN118562882B/zh active Active
-
2022
- 2022-07-14 US US17/865,292 patent/US11945865B2/en active Active
- 2022-11-10 AU AU2022268355A patent/AU2022268355B2/en active Active
-
2023
- 2023-01-31 JP JP2023012793A patent/JP2023059873A/ja active Pending
-
2024
- 2024-02-21 US US18/583,551 patent/US20240182567A1/en active Pending
-
2025
- 2025-01-10 JP JP2025004349A patent/JP2025065142A/ja active Pending
- 2025-07-04 AU AU2025205147A patent/AU2025205147B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025065142A5 (https=) | ||
| JP2023059873A5 (https=) | ||
| JP2021106605A5 (https=) | ||
| JP2023123502A5 (https=) | ||
| JP2021094037A5 (https=) | ||
| JP2021087455A5 (https=) | ||
| JP2024023228A5 (https=) | ||
| JP2021177771A5 (https=) | ||
| JP2021137024A5 (https=) | ||
| JP2019527557A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| JP2021526844A5 (https=) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| CN107709367A (zh) | 新型多肽 | |
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| WO2021188736A1 (en) | MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF | |
| IL301995A (en) | Cells comprising t cell-antigen couplers and uses thereof | |
| JPWO2020228825A5 (https=) | ||
| JPWO2021184673A5 (https=) | ||
| JPWO2020076992A5 (https=) | ||
| CA3233085A1 (en) | Composition of recombinant antigen binding molecules and method of making and using thereof | |
| JPWO2023034922A5 (https=) | ||
| JPWO2019245991A5 (https=) | ||
| CN115335407A (zh) | 结合cd19的嵌合抗原受体及其用途 |